Synagis®: Stay on track with your baby's RSV protection

Get every dose of Synagis your doctor prescribes—even if your baby looks healthy.

Every shot your doctor prescribes is essential if you want to help protect your baby from severe RSV disease. Even as your little one gets bigger and stronger, those growing lungs still need protection.

A preemie's lungs are still developing and have fewer 'branches' of airways

Remember that each dose of Synagis only lasts for about 28 to 30 days, so you don’t want to skip or postpone any shots. Keep reading to learn more.

Don't assume RSV season is over when springtime comes around.

RSV season usually starts in the fall and continues into spring, but it can be different from place to place. So don't take a spring break from your baby's RSV protection—keep going to all of those Synagis appointments until your doctor says otherwise.

Keep reading to learn about how every region's RSV season is unique.

Get support throughout RSV season.

Just getting through RSV season can seem like a challenge, but you’re not alone. You can find support, helpful reminders and even tips from parents who’ve been there in our Helping HandSM program.

** Adapted from Moore KL, Persaud TVN. The Developing Human: Clinically Oriented Embryology. 7th ed. Philadelphia, Pa: Saunders; 2003:245-251.

Important Safety Information

Synagis® (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.